Quoin Pharmaceuticals, Ltd.
QNRXHealthcareNASDAQBiotechnology · Last scanned Oct 19, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Oct 16
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. At a $18.7M market cap, Quoin Pharmaceuticals, Ltd. ranks as a micro-cap company within healthcare. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
Market Cap
$18.7M
Beta
1.75
P/E (TTM)
—
P/E (Fwd)
-1.22
EPS (TTM)
$-5.67
EPS (Fwd)
$-3.19
ROE
-575.7%
ROA
-114.6%
Cash
$10.8M
Total Debt
$2.0M
Free CF
-$8.0M
52W Change
-76.2%
Annual Financials
Cash vs Debt
Where QNRX stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, QNRX finished 29.09% below its 150-day moving average ($5.50) and 39.91% below its 200-day moving average ($6.49). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is QNRX overbought or oversold?
At the October 19, 2026 close, QNRX's RSI(14) was 18.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Quoin Pharmaceuticals, Ltd. holds $10.8M in cash against $2.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$8.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -575.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.75 means QNRX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Quoin Pharmaceuticals, Ltd. and its sector.